The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Talquetamab and teclistamab in triple-class refractory myeloma: important practical considerations
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the use of teclistamab and talquetamab in the treatment of triple-class refractory multiple myeloma, highlighting their promising efficacy. Dr Ramasamy also comments on the importance of closely monitoring for side effects associated with these agents, including infection, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
